<DOC>
	<DOCNO>NCT02032875</DOCNO>
	<brief_summary>This trial open participant receive liver transplant cirrhosis due chronic HCV . All subject treat daclatasvir+sofosbuvir+ribavirin follow 24 week post treatment . Under certain condition , treatment duration could extend cirrhotic participant . The study test efficacy safety combination treatment HCV cirrhotic post transplant patient .</brief_summary>
	<brief_title>Phase III Daclatasvir , Sofosbuvir , Ribavirin Cirrhotic Participants Participants Post-liver Transplant</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Participants must able understand agree comply prescribe dose regimen procedure , report regularly schedule study visit , reliably communicate study personnel adverse event concomitant medication Participants chronically infect hepatitis C virus ( HCV ) Genotype 1 , 2 , 3 , 4 , 5 , 6 HCV RNA viral load ≥10,000 IU/mL screen Participants may treatmentnaïve treatmentexperienced Cirrhotic participant must cirrhosis confirmed biopsy , Fibroscan fibrotest Aspartate aminotransferase platelet ratio index ( APRI ) criterion outline protocol Posttransplant participant must least 3 month posttransplant evidence moderate severe rejection History multiorgan transplant , exception dual transplantation liver/kidney , prohibit Current known history cancer ( follow exception : In situ carcinoma cervix , adequately treat basal squamous cell carcinoma skin , hepatocellular carcinoma within Milan criterion transplantation ) within 5 year prior screen Evidence ongoing medical condition contribute chronic liver disease HCV ( , limit : hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) History HIV infection chronic hepatitis B virus ( HBV ) document HBV serology ( e.g. , HBsAgseropositive ) . Participants resolve HBV infection may participate ( e.g. , HBcAbseropositive concurrent HBsAgseronegative ) Active hospitalization decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>